Viridian Therapeutics is advancing its pipeline with positive phase 3 results for veligrotug in thyroid eye disease and plans a BLA submission in November 2025. VRDN is expanding its TED program with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback